Biotechnology
Commented by Stefan Feulner on June 25th, 2021 | 12:36 CEST
Nordex, XPhyto Therapeutics, Siemens AG - Growth without end
The Federal Reserve paves the way. After discussions around possible early interest rate hikes flared up last week on the occasion of the Federal Reserve's Open Market Committee, FED head Jerome Powell came forward in person yesterday and dampened burgeoning inflation concerns. While the effects of the pickup in economic activity at the end of the Corona pandemic were stronger than forecast, they should fade over time. Therefore, the loose monetary policy will continue to drive growth - a breeding ground for development and technology stocks and further rising prices.
Read
Commented by Stefan Feulner on June 24th, 2021 | 12:52 CEST
CureVac, Cardiol Therapeutics, Bayer - Where we go from here
Biotechnology has an extraordinary impact on our lives. The perception and appreciation of the future industry of the 21st century has increased significantly in the past year. All thanks due to the race for vaccines against the coronavirus. Yet investing in a biotechnology startup requires patience and a willingness to take risks. The risk that an active ingredient will not work in the end, as the example of CureVac shows, is high. On the other hand, however, investors have the opportunity to multiply their invested capital in the event of successful approval.
Read
Commented by Carsten Mainitz on June 22nd, 2021 | 12:36 CEST
MorphoSys, Defence Therapeutics, Formycon - Biotechnology shares with great potential
In the wake of the corona pandemic, companies such as BioNTech, Pfizer and Moderna demonstrated how quickly and safely vaccines can be developed and mass-produced using innovative biotechnological processes. Biotech stocks have risen in favor again, even outside Covid-19. However, some stocks lag behind the price targets forecast by experts, while others are slowly moving (again) in the right direction. We look at three stocks that offer excellent opportunities at the current price level.
Read
Commented by André Will-Laudien on June 18th, 2021 | 12:49 CEST
CureVac, BioNTech, Novavax, XPhyto Therapeutics - The Covid giants and the sellout!
How quickly the tide can turn in the environment of the Corona pandemic can be seen in the vaccine manufacturers and test providers. BioNTech's share price has been rising steadily since the start of the vaccination campaign in Germany, and minor reports of potential side effects are hardly disturbing. In the case of test provider NanoRepro, the bull market of recent months is turning into a total sell-off, with the share losing over 70%. And then there is the Tübingen-based biotech Company CureVac. Delays in approval and a shock on efficacy send the share down by a whole 50% in one day. We take a closer look at the situation.
Read
Commented by Nico Popp on June 15th, 2021 | 13:15 CEST
CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio
Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.
Read
Commented by Stefan Feulner on June 7th, 2021 | 09:37 CEST
Bayer, Defence Therapeutics, MorphoSys - A paradigm shift in biotechnology
The search for a vaccine against the Coronavirus brought biotechnology back into the focus of investors last year. Companies such as BioNTech or CureVac were able to multiply in this regard. In 2020, the biotech sector in Germany raised a record sum of EUR 3 billion, and the trend is rising sharply. The fight against incurable diseases and the development of important innovations such as vaccines, cancer therapies, or sustainable products lift the segment into higher realms and offer attractive investment opportunities.
Read
Commented by André Will-Laudien on June 7th, 2021 | 08:32 CEST
CureVac, Cardiol Therapeutics, Formycon, NanoRepro - Pharma stocks with potential!
In Germany, around 231,000 people died as a result of cancer in 2019. As reported by the Federal Statistical Office, cancer was the cause of a quarter of all deaths. This proportion has hardly changed within 20 years, even though the number of cancer deaths has increased by around 10% since 1999. The precise number 1 cause of widespread disease in Germany is cardiovascular disease, such as heart failure, coronary heart disease and myocardial infarction. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. So research continues to be in demand. We look at interesting representatives of the industry.
Read
Commented by Nico Popp on June 1st, 2021 | 10:05 CEST
Defence Therapeutics, CureVac, BioNTech: Vaccine against cancer makes progress
Biotechnology is the map to the holy grail that needs to be found as quickly as possible for many sick people. When the pandemic broke out last year, it accelerated some developments. For example, mRNA technology, which BioNTech and CureVac had already been researching, was successfully launched as a vaccine technology. It is well known that this can be used to develop effective vaccines against coronaviruses and target diseases such as cancer. BioNTech has this option in mind and holds good cards to succeed with it. The young biotech startup Defence Therapeutics has also recently reported its first successes in the fight against cancer.
Read
Commented by Stefan Feulner on May 10th, 2021 | 09:14 CEST
CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!
The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.
Read
Commented by Stefan Feulner on April 28th, 2021 | 07:04 CEST
CureVac, PsyBio, Evotec - Revolution in the billion-dollar market!
The anxiety and limitations associated with the coronavirus pose major challenges for people suffering from depression. Officially, around 350 million people worldwide live with depression, but the number of unreported cases is significantly higher. At the moment, the number one cause of the disease is only combated with antidepressants; there are hardly any alternative treatment methods without severe side effects. A completely new field is currently emerging that could completely eclipse existing drugs, with incredible potential for the young companies.
Read